Bharat Biotech’s Ankleshwar unit gets nod to make Covaxin
Bharat Biotech recently stated that products manufactured from Ankleshwar will be available for supplies during September.
Hyderabad: Union Chemicals and Fertilizers and Health Minister Mansukh Mandaviya on Tuesday said the government has given nod to Bharat Biotech’s Ankleshwar plant to produce Covid-19 vaccine Covaxin.
“Govt of India approves vaccine manufacturing facility for production of @BharatBiotech”s #Covaxin in Ankleshwar, Gujarat,” he tweeted. The approval would help increase availability of Covid-19 vaccines in the country, he added.
“Following PM @NarendraModi ji”s vision of #SabkoVaccineMuftVaccine, this will increase vaccine availability & accelerate the world’s largest vaccine drive,” the Minister said.
Bharat Biotech recently stated that products manufactured from Ankleshwar will be available for supplies during September. This is based on the company’s 120-day timeline for manufacturing, testing, release, regulatory approvals, and distribution.
In May this year, the Hyderabad-based vaccine maker said that it plans to produce an additional 200 million doses of Covaxin at its subsidiary’s Ankleshwar-based facility. It said that it would utilise the manufacturing plant of its wholly-owned unit – Chiron Behring, to add another 200 million doses of Covaxin.
